![Western Blot: BICD1 Antibody [NBP1-78735] - Whole cell lysate from Jurkat (15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded), 293T (T; 50 mcg) and HeLa (H; 50 mcg) cells. Affinity purified rabbit anti-BICD1 antibody used for WB at 0.1 mcg/ml (A) and 1 mcg/ml (B) and used for IP at 6 mcg/mg lysate. BICD1 was also immunoprecipitated by rabbit anti-BICD1 antibody NBP1-78734 which recognizes an upstream epitope.](http://images.novusbio.com/fullsize/BICD1-Antibody-Western-Blot-NBP1-78735-img0002.jpg "Western Blot: BICD1 Antibody [NBP1-78735] - Whole cell lysate from Jurkat (15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded), 293T (T; 50 mcg) and HeLa (H; 50 mcg) cells. Affinity purified rabbit anti-BICD1 antibody used for WB at 0.1 mcg/ml (A) and 1 mcg/ml (B) and used for IP at 6 mcg/mg lysate. BICD1 was also immunoprecipitated by rabbit anti-BICD1 antibody NBP1-78734 which recognizes an upstream epitope.")
| Reactivity | HuSpecies Glossary |
| Applications | WB, IP, Mycoplasma |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Format | BSA Free |
| Concentration | 1.0 mg/ml |
| Description | Novus Biologicals Rabbit BICD1 Antibody - BSA Free (NBP1-78735) is a polyclonal antibody validated for use in WB and IP. Anti-BICD1 Antibody: Cited in 3 publications. All Novus Biologicals antibodies are covered by our 100% guarantee. |
| Immunogen | The immunogen for this product maps to a region between residue 550 and 600 of human Bicaudal D Homolog 1 using the numbering given in entry NP_001705.2 (GeneID 636). |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | BICD1 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Publications |
|
| Storage | Store at 4C. Do not freeze. |
| Buffer | Tris-Citrate/Phosphate (pH 7.0 - 8.0) |
| Preservative | 0.09% Sodium Azide |
| Concentration | 1.0 mg/ml |
| Purity | Immunogen affinity purified |
Secondary Antibodies |
Isotype Controls |
Research Areas for BICD1 Antibody (NBP1-78735)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | BICD1 |
| Uniprot |
|
![Western Blot: BICD1 Antibody [NBP1-78735] - Effect of hypoxia on the interaction between HIF-1 alpha and BICD1. Cells were pretreated with MG132 (1 uM) for 30 min prior to hypoxia treatment for 24 h. Co-immunoprecipitation of HIF-1 alpha with IgG and BICD1 were shown in left panel. Total protein expressions in lysate were shown in right panel. n = 3. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41418-018-0241-1), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BICD1-Antibody-Western-Blot-NBP1-78735-img0004.jpg "Western Blot: BICD1 Antibody [NBP1-78735] - Effect of hypoxia on the interaction between HIF-1 alpha and BICD1. Cells were pretreated with MG132 (1 uM) for 30 min prior to hypoxia treatment for 24 h. Co-immunoprecipitation of HIF-1 alpha with IgG and BICD1 were shown in left panel. Total protein expressions in lysate were shown in right panel. n = 3. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41418-018-0241-1), licensed under a CC-BY license.")
![Western Blot: BICD1 Antibody [NBP1-78735] - Role of BICD1 in UCB-MSCs survival under hypoxia. a, b The UCB-MSCs were transfected with BICD1 or NT siRNA for 24 h prior to hypoxia treatment. a Cells were exposed to various durations of hypoxia (0–72 h). Cell viability of UCB-MSCs was measured by WST-1 cell viability assay. n = 8. b Cells were incubated in normoxia or hypoxia conditions for 72 h. Representative images of experimental groups at 0, 24, 48, & 72 h of normoxia or hypoxia incubation are presented. Red-marked cells in representative images indicate PI-positive cells. n = 4. Scale bars are 50 μm (Magnification, × 200). cBICD1 or NT siRNA-transfected cells were incubated in hypoxia for 24 h. Cleaved caspase-9, cleaved caspase-3, & beta -Actin protein expressions were detected by western blot analysis. n = 4. d Cells were transfected with BICD1 or NT siRNA for 24 h prior to hypoxia treatment for 48 h. The percentages of apoptotic cells were analyzed by Annexin V/PI analysis, measured by flowcytometer. Annexin V-positive cells were considered as apoptotic cells. n = 4. Quantitative data are presented as a mean ± S.E.M. All blot images are representative. *p < 0.05 vs. normoxia control with NT siRNA transfection, #p < 0.05 vs. hypoxia with NT siRNA transfection. e The UCB-MSCs were transfected with pcDNA3.1/BICD1-cEGFP vector, pcDNA3.1/cEGFP vector, HIF1A siRNA or NT siRNA for 24 h prior to hypoxia treatment for 72 h. Cell viability data are presented as a mean ± S.E.M. n = 5. *p < 0.05 vs. normoxia control with pcDNA3.1/cEGFP vector & NT siRNA cotransfection, #p < 0.05 vs. hypoxia control with pcDNA3.1/cEGFP vector & NT siRNA cotransfection, @p < 0.05 vs. hypoxia control with pcDNA3.1/BICD1-cEGFP vector & NT siRNA cotransfection Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30464225), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-78735_rabbit-polyclonal-bicd1-antibody-310202416171413.jpg "Western Blot: BICD1 Antibody [NBP1-78735] - Role of BICD1 in UCB-MSCs survival under hypoxia. a, b The UCB-MSCs were transfected with BICD1 or NT siRNA for 24 h prior to hypoxia treatment. a Cells were exposed to various durations of hypoxia (0–72 h). Cell viability of UCB-MSCs was measured by WST-1 cell viability assay. n = 8. b Cells were incubated in normoxia or hypoxia conditions for 72 h. Representative images of experimental groups at 0, 24, 48, & 72 h of normoxia or hypoxia incubation are presented. Red-marked cells in representative images indicate PI-positive cells. n = 4. Scale bars are 50 μm (Magnification, × 200). cBICD1 or NT siRNA-transfected cells were incubated in hypoxia for 24 h. Cleaved caspase-9, cleaved caspase-3, & beta -Actin protein expressions were detected by western blot analysis. n = 4. d Cells were transfected with BICD1 or NT siRNA for 24 h prior to hypoxia treatment for 48 h. The percentages of apoptotic cells were analyzed by Annexin V/PI analysis, measured by flowcytometer. Annexin V-positive cells were considered as apoptotic cells. n = 4. Quantitative data are presented as a mean ± S.E.M. All blot images are representative. *p < 0.05 vs. normoxia control with NT siRNA transfection, #p < 0.05 vs. hypoxia with NT siRNA transfection. e The UCB-MSCs were transfected with pcDNA3.1/BICD1-cEGFP vector, pcDNA3.1/cEGFP vector, HIF1A siRNA or NT siRNA for 24 h prior to hypoxia treatment for 72 h. Cell viability data are presented as a mean ± S.E.M. n = 5. *p < 0.05 vs. normoxia control with pcDNA3.1/cEGFP vector & NT siRNA cotransfection, #p < 0.05 vs. hypoxia control with pcDNA3.1/cEGFP vector & NT siRNA cotransfection, @p < 0.05 vs. hypoxia control with pcDNA3.1/BICD1-cEGFP vector & NT siRNA cotransfection Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30464225), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: BICD1 Antibody [NBP1-78735] - Effect of hypoxia on the interaction between HIF1 alpha & BICD1. a Co-immunoprecipitation of HIF1 alpha , Dynein IC, Importin alpha 3, RanBP2 w/ IgG & BICD1 antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. b Cells immunostained w/ HIF1 alpha & BICD1-specific antibodies. Scale bars are 8 μm (Magnification, × 1,000). White arrow heads indicate co-localization of HIF1 alpha w/ BICD1. c Interaction between HIF1 alpha & BICD1 (HIF1 alpha /BICD1, red) analyzed by PLA. Scale bars are 8 μm (Magnification, × 1,000). n = 6. *p < 0.05 vs. normoxia control. d–f Cells pretreated w/ MG132 (1 μM) for 30 min prior to hypoxia treatment for 24 h. d Co-immunoprecipitation of HIF1 alpha w/ IgG & BICD1 shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. e Cells immunostained w/ HIF1 alpha & BICD1-specific antibodies. White arrow heads indicate co-localization of HIF1 alpha w/ BICD1 in MG132-pretreated UCB-MSCs. Scale bars are 8 μm (Magnification, × 1,000). n = 5. f HIF1 activity measured by dual luciferase reporter assay. n = 6. *p < 0.05 vs. normoxia control w/ MG132 pretreatment. g, h Cells transfected w/ BICD1 or NT siRNA for 24 h prior to hypoxia treatment for 24 h. g Co-immunoprecipitation of Dynein IC w/ IgG & HIF1 alpha antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. h Interaction between HIF1 alpha & Dynein IC (HIF1 alpha /Dynein IC, red) analyzed by PLA. Scale bars are 8 μm (Magnification, × 1,000). Quantitative data are presented as a mean ± S.E.M. All blots & immunofluorescence images are representative. *p < 0.05 vs. normoxia control w/ NT siRNA transfection, #p < 0.05 vs. hypoxia w/ NT siRNA transfection Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30464225), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-78735_rabbit-polyclonal-bicd1-antibody-310202416171451.jpg "Western Blot: BICD1 Antibody [NBP1-78735] - Effect of hypoxia on the interaction between HIF1 alpha & BICD1. a Co-immunoprecipitation of HIF1 alpha , Dynein IC, Importin alpha 3, RanBP2 w/ IgG & BICD1 antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. b Cells immunostained w/ HIF1 alpha & BICD1-specific antibodies. Scale bars are 8 μm (Magnification, × 1,000). White arrow heads indicate co-localization of HIF1 alpha w/ BICD1. c Interaction between HIF1 alpha & BICD1 (HIF1 alpha /BICD1, red) analyzed by PLA. Scale bars are 8 μm (Magnification, × 1,000). n = 6. *p < 0.05 vs. normoxia control. d–f Cells pretreated w/ MG132 (1 μM) for 30 min prior to hypoxia treatment for 24 h. d Co-immunoprecipitation of HIF1 alpha w/ IgG & BICD1 shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. e Cells immunostained w/ HIF1 alpha & BICD1-specific antibodies. White arrow heads indicate co-localization of HIF1 alpha w/ BICD1 in MG132-pretreated UCB-MSCs. Scale bars are 8 μm (Magnification, × 1,000). n = 5. f HIF1 activity measured by dual luciferase reporter assay. n = 6. *p < 0.05 vs. normoxia control w/ MG132 pretreatment. g, h Cells transfected w/ BICD1 or NT siRNA for 24 h prior to hypoxia treatment for 24 h. g Co-immunoprecipitation of Dynein IC w/ IgG & HIF1 alpha antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. h Interaction between HIF1 alpha & Dynein IC (HIF1 alpha /Dynein IC, red) analyzed by PLA. Scale bars are 8 μm (Magnification, × 1,000). Quantitative data are presented as a mean ± S.E.M. All blots & immunofluorescence images are representative. *p < 0.05 vs. normoxia control w/ NT siRNA transfection, #p < 0.05 vs. hypoxia w/ NT siRNA transfection Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30464225), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: BICD1 Antibody [NBP1-78735] - Effect of hypoxia on the interaction between HIF1 alpha & BICD1. a Co-immunoprecipitation of HIF1 alpha , Dynein IC, Importin alpha 3, RanBP2 w/ IgG & BICD1 antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. b Cells immunostained w/ HIF1 alpha & BICD1-specific antibodies. Scale bars are 8 μm (Magnification, × 1,000). White arrow heads indicate co-localization of HIF1 alpha w/ BICD1. c Interaction between HIF1 alpha & BICD1 (HIF1 alpha /BICD1, red) analyzed by PLA. Scale bars are 8 μm (Magnification, × 1,000). n = 6. *p < 0.05 vs. normoxia control. d–f Cells pretreated w/ MG132 (1 μM) for 30 min prior to hypoxia treatment for 24 h. d Co-immunoprecipitation of HIF1 alpha w/ IgG & BICD1 shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. e Cells immunostained w/ HIF1 alpha & BICD1-specific antibodies. White arrow heads indicate co-localization of HIF1 alpha w/ BICD1 in MG132-pretreated UCB-MSCs. Scale bars are 8 μm (Magnification, × 1,000). n = 5. f HIF1 activity measured by dual luciferase reporter assay. n = 6. *p < 0.05 vs. normoxia control w/ MG132 pretreatment. g, h Cells transfected w/ BICD1 or NT siRNA for 24 h prior to hypoxia treatment for 24 h. g Co-immunoprecipitation of Dynein IC w/ IgG & HIF1 alpha antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. h Interaction between HIF1 alpha & Dynein IC (HIF1 alpha /Dynein IC, red) analyzed by PLA. Scale bars are 8 μm (Magnification, × 1,000). Quantitative data are presented as a mean ± S.E.M. All blots & immunofluorescence images are representative. *p < 0.05 vs. normoxia control w/ NT siRNA transfection, #p < 0.05 vs. hypoxia w/ NT siRNA transfection Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30464225), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-78735_rabbit-polyclonal-bicd1-antibody-31020241616184.jpg "Western Blot: BICD1 Antibody [NBP1-78735] - Effect of hypoxia on the interaction between HIF1 alpha & BICD1. a Co-immunoprecipitation of HIF1 alpha , Dynein IC, Importin alpha 3, RanBP2 w/ IgG & BICD1 antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. b Cells immunostained w/ HIF1 alpha & BICD1-specific antibodies. Scale bars are 8 μm (Magnification, × 1,000). White arrow heads indicate co-localization of HIF1 alpha w/ BICD1. c Interaction between HIF1 alpha & BICD1 (HIF1 alpha /BICD1, red) analyzed by PLA. Scale bars are 8 μm (Magnification, × 1,000). n = 6. *p < 0.05 vs. normoxia control. d–f Cells pretreated w/ MG132 (1 μM) for 30 min prior to hypoxia treatment for 24 h. d Co-immunoprecipitation of HIF1 alpha w/ IgG & BICD1 shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. e Cells immunostained w/ HIF1 alpha & BICD1-specific antibodies. White arrow heads indicate co-localization of HIF1 alpha w/ BICD1 in MG132-pretreated UCB-MSCs. Scale bars are 8 μm (Magnification, × 1,000). n = 5. f HIF1 activity measured by dual luciferase reporter assay. n = 6. *p < 0.05 vs. normoxia control w/ MG132 pretreatment. g, h Cells transfected w/ BICD1 or NT siRNA for 24 h prior to hypoxia treatment for 24 h. g Co-immunoprecipitation of Dynein IC w/ IgG & HIF1 alpha antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. h Interaction between HIF1 alpha & Dynein IC (HIF1 alpha /Dynein IC, red) analyzed by PLA. Scale bars are 8 μm (Magnification, × 1,000). Quantitative data are presented as a mean ± S.E.M. All blots & immunofluorescence images are representative. *p < 0.05 vs. normoxia control w/ NT siRNA transfection, #p < 0.05 vs. hypoxia w/ NT siRNA transfection Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30464225), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: BICD1 Antibody [NBP1-78735] - Involvement of Akt/GSK3 beta pathway in BICD1-mediated HIF1 alpha nuclear translocation. a–e The UCB-MSCs were transfected with GSK3 beta or NT siRNA for 24 h prior to hypoxia treatment for 24 h. a Co-immunoprecipitation of HIF1 alpha & Dynein IC with IgG & BICD1 antibodies were shown in left panel. Total protein expressions in lysate were shown in right panel. n = 3. b Interaction between HIF1 alpha & BICD1 (HIF1 alpha /BICD1, red) was analyzed by PLA assay. Scale bars are 8 μm (Magnification, × 1,000). n = 5. c HIF1 alpha , Lamin A/C, & alpha -Tubulin in cytosolic & nuclear fractionized samples were detected by western blot. n = 4. d Cells were immunostained with HIF1 alpha -specific antibody. Scale bars are 8 μm (Magnification, × 1,000). n = 4. e HIF1 activities in NT or GSK3 beta siRNA-transfected cells were analyzed by dual luciferase reporter assay. n = 6. Quantitative data are presented as a mean ± S.E.M. All blots & immunofluorescence images are representative. *p < 0.05 vs. normoxia control with NT siRNA transfection, #p < 0.05 vs. hypoxia with NT siRNA transfection Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30464225), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-78735_rabbit-polyclonal-bicd1-antibody-31020241616183.jpg "Western Blot: BICD1 Antibody [NBP1-78735] - Involvement of Akt/GSK3 beta pathway in BICD1-mediated HIF1 alpha nuclear translocation. a–e The UCB-MSCs were transfected with GSK3 beta or NT siRNA for 24 h prior to hypoxia treatment for 24 h. a Co-immunoprecipitation of HIF1 alpha & Dynein IC with IgG & BICD1 antibodies were shown in left panel. Total protein expressions in lysate were shown in right panel. n = 3. b Interaction between HIF1 alpha & BICD1 (HIF1 alpha /BICD1, red) was analyzed by PLA assay. Scale bars are 8 μm (Magnification, × 1,000). n = 5. c HIF1 alpha , Lamin A/C, & alpha -Tubulin in cytosolic & nuclear fractionized samples were detected by western blot. n = 4. d Cells were immunostained with HIF1 alpha -specific antibody. Scale bars are 8 μm (Magnification, × 1,000). n = 4. e HIF1 activities in NT or GSK3 beta siRNA-transfected cells were analyzed by dual luciferase reporter assay. n = 6. Quantitative data are presented as a mean ± S.E.M. All blots & immunofluorescence images are representative. *p < 0.05 vs. normoxia control with NT siRNA transfection, #p < 0.05 vs. hypoxia with NT siRNA transfection Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30464225), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot MARK2 [p Thr595] Antibody - BSA Free](https://images.novusbio.com/images/nbp1-78028_rabbit-polyclonal-mark2-p-thr595-antibody-255202313135151.jpg)
![Western Blot MARK2 [p Thr595] Antibody - BSA Free](https://images.novusbio.com/images/MARK2-[p-Thr595]-Antibody-Western-Blot-NBP1-78028-img0001.jpg)
![Western Blot MARK2 [p Thr595] Antibody - BSA Free](https://images.novusbio.com/images/MARK2-[p-Thr595]-Antibody-Western-Blot-NBP1-78028-img0002.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")